Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti

Evoke Pharma (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today announced additional findings from its comparative exposure pharmacokinetic (PK) trial for Gimoti™, the Company’s novel nasal spray delivery of metoclopramide for the treatment of symptoms associated with gastroparesis. Further analysis of the PK data by sex revealed statistically significant differences in exposure between women and men given the same metoclopramide dose (nasal and oral).

As quoted in the press release:

“The discovery of a sex-based PK exposure differential for metoclopramide and Gimoti is exciting, as we believe the exposure differences may explain the efficacy results seen in our previous clinical trials where Gimoti reduced symptoms of gastroparesis in women, but not men,” commented Dave Gonyer, President and CEO. “We hope this finding can help with future treatment decisions for those who suffer from symptoms of gastroparesis.”

Click here to read the full press release.